Opioids and Immunotherapy in Advanced Lung Cancer
Part of Brain & nervous system clinical trials.
This trial studies how opioid pain medicines affect the effectiveness of immunotherapy in people with advanced lung cancer who have moderate to severe pain. It may help doctors understand if pain management influences treatment outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have advanced lung cancer (stage IIIb or IV) confirmed by biopsy.
- You are about to start immunotherapy (immune checkpoint inhibitors).
- You have moderate to severe pain, rated 4 or higher on a 0-10 scale.
- You are using or will use opioid pain medications (like morphine, oxycodone, or fentanyl).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a three-drug combination (ipilimumab, nivolumab, and nogapendekin alfa inbakicept) as a first treatment for people with stage IV or recurrent non-small cell lung cancer. The goal is to see if this approach can help your immune system fight the cancer more effectively.
This trial tests whether adding the anti-inflammatory drug diclofenac can help people with advanced non-small cell lung cancer whose tumors are growing while on a single immunotherapy drug. You must have been on immunotherapy for at least 12 weeks and have a growing tumor, but your doctor does not plan to change your treatment right away.
This trial tests a combination of ivonescimab and docetaxel for people with advanced non-small cell lung cancer who have had a long response (11-15 months without the cancer getting worse) to first-line immunotherapy. The goal is to see if adjusting treatment based on ctDNA-MRD levels can improve outcomes.
This trial tests if adding acupuncture to standard immunotherapy and chemotherapy helps people with advanced lung cancer. It is for those who have not had treatment before and whose tumors have low PD-L1 levels.
This study tests a combination of chemotherapy and immunotherapy in people with advanced non-small cell lung cancer that has spread or cannot be removed with surgery. The goal is to see how well this treatment works in patients with different levels of daily activity.
This trial tests whether using a blood test to guide treatment can improve outcomes for people with advanced non-small cell lung cancer who are starting immunotherapy for the first time. Participants will receive standard immunotherapy tailored to their individual risk profile.
Hear when a new Pain Management trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.